Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul;75(7):1543-1545.
doi: 10.1111/all.14348.

Asthma and COVID-19: Is asthma a risk factor for severe outcomes?

Sebastian L Johnston  1
Affiliations
Editorial

Asthma and COVID-19: Is asthma a risk factor for severe outcomes?

Sebastian L Johnston. Allergy. 2020 Jul.
No abstract available

Keywords: COVID-19; asthma.

PubMed Disclaimer

Conflict of interest statement

Dr Johnston reports personal fees from Virtus Respiratory Research, Myelo TherapeuticsÐmbH, Concert Pharmaceuticals, Bayer, Synairgen, Novartis, Boehringer Ingelheim, Chiesi, Gerson Lehrman Group, resTORbio, Bioforce, Materia Medical Holdings, PrepBio Pharma, Pulmotect, Virion Health, Lallemand Pharma and AstraZeneca, outside the submitted work; In addition, Dr Johnston has a patent: Wark PA, Johnston SL, Holgate ST, Davies DE, Antivirus Therapy for Respiratory diseases, UK patent application No. GB 0405 634.7, 12 March 2004, with royalties paid, a patent Wark PA, Johnston SL, Holgate ST, Davies DE, Interferon‐Beta for Anti‐Virus Therapy for Respiratory Diseases, International Patent Application No. PCT/GB05/50031, 12 March 2004, with royalties paid, and a patent Davies DE, Wark PA, Holgate ST, Johnston SL. Interferon Lambda Therapy for the Treatment of Respiratory disease. UK patent application No. 6779645.9, granted 15th August 2012, licensed. SLJ is the Asthma UK Clinical Chair (grant CH11SJ).

Comment in

References

    1. Zhang J‐J, Dong X, Cao Y‐Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020;75:1730‐1741. - PubMed
    1. Sotgiu G, Gerli GA, Centanni S, et al. Advanced forecasting of SARS‐CoV‐2 related deaths in Italy, Germany, Spain, and New York State. Allergy. 2020;75:1813‐1815. - PMC - PubMed
    1. Corne JM, Marshall C, Smith S, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non‐asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831‐834. - PubMed
    1. Jackson DJ, Trujillo‐Torralbo M‐B, del‐Rosario J, et al. The influence of asthma control on the severity of virus‐induced asthma exacerbations. J Allergy Clin Immunol. 2015;136(2):497‐500.e3. - PubMed
    1. Sykes A, Edwards MR, Macintyre J, et al. Rhinovirus 16‐induced IFN‐alpha and IFN‐beta are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012;129(6):1506‐1514.e6. - PubMed

Publication types

MeSH terms